JAY GERTZ

Professor

Oncological Sciences

  • Professor
    Oncological Sciences
  • Adjunct Professor
    Biomedical Engineering

GRANTS

  • EXTERNAL GRANT OR CONTRACT
    ADVANCING HORMONE THERAPY FOR ENDOMETRIAL CANCER
    8 Aug 2025 - 15 Feb 2027
  • EXTERNAL GRANT OR CONTRACT
    ADVANCING HORMONE THERAPY FOR ENDOMETRIAL CANCER
    8 Aug 2025 - 15 Feb 2027
  • EXTERNAL GRANT OR CONTRACT
    ADVANCING HORMONE THERAPY FOR ENDOMETRIAL CANCER
    8 Aug 2025 - 15 Feb 2027
  • EXTERNAL GRANT OR CONTRACT
    ADVANCING HORMONE THERAPY FOR ENDOMETRIAL CANCER
    8 Aug 2025 - 15 Feb 2027
  • EXTERNAL GRANT OR CONTRACT
    ADVANCING HORMONE THERAPY FOR ENDOMETRIAL CANCER
    8 Aug 2025 - 15 Feb 2027
  • EXTERNAL GRANT OR CONTRACT
    ADVANCING HORMONE THERAPY FOR ENDOMETRIAL CANCER
    8 Aug 2025 - 15 Feb 2027
  • EXTERNAL GRANT OR CONTRACT
    ADVANCING HORMONE THERAPY FOR ENDOMETRIAL CANCER
    8 Aug 2025 - 15 Feb 2027
  • EXTERNAL GRANT OR CONTRACT
    ADVANCING HORMONE THERAPY FOR ENDOMETRIAL CANCER
    8 Aug 2025 - 15 Feb 2027
  • EXTERNAL GRANT OR CONTRACT
    CANCER CENTER SUPPORT GRANT -- GERTZ
    NIH NATIONAL CANCER INSTITUTE1 May 2025 - 15 Nov 2025
    NIH NATIONAL CANCER INSTITUTE
  • EXTERNAL GRANT OR CONTRACT
    HUNTSMAN CANCER INSTITUTE POST-BACCALAUREATE PROGRAM IN CANCER RESEARCH
    1 Jan 2025 - 31 Dec 2027
  • EXTERNAL GRANT OR CONTRACT
    CANCER CENTER SUPPORT GRANT -- GERTZ
    NIH NATIONAL CANCER INSTITUTE1 Aug 2024 - 30 Apr 2025
    NIH NATIONAL CANCER INSTITUTE
  • EXTERNAL GRANT OR CONTRACT
    PHASE IV - ANALYSIS OF SHIVANKA COMPOUNDS IMPACT ON GENE EXPRESSION IN HCI-011
    SHIVANKA RESEARCH LLC27 Jun 2024 - 31 Oct 2024
    SHIVANKA RESEARCH LLC
  • EXTERNAL GRANT OR CONTRACT
    EXPANSION AND CHARACTERIZATION OF HUMAN ENDOMETRIAL CANCER MODELS
    1 Jun 2024 - 30 Oct 2026
  • EXTERNAL GRANT OR CONTRACT
    THE COMBINED ROLE OF ARID1A LOSS AND ESTROGEN SIGNALING IN ENDOMETRIAL CANCER
    4 Mar 2024 - 28 Feb 2029
  • EXTERNAL GRANT OR CONTRACT
    PHASE III - ANALYSIS OF SHIVANKA COMPOUNDS IMPACT ON GENE EXPRESSION IN ER WILDTYPE AND MUTANT BREAST CANCER MODELS
    27 Sep 2023 - 26 Jan 2024
  • EXTERNAL GRANT OR CONTRACT
    MOLECULAR CROSSTALK BETWEEN ESTROGENS AND PROGESTOGENS IN ENDOMETRIAL CANCER
    1 Sep 2023 - 31 Aug 2027
  • EXTERNAL GRANT OR CONTRACT
    PROGESTIN THERAPY FOR ENDOMETRIAL CANCER
    1 Aug 2023 - 31 Jul 2027
  • EXTERNAL GRANT OR CONTRACT
    MECHANISMS OF TAMOXIFEN-ASSOCIATED ENDOMETRIAL CANCER RISK
    NIH NATIONAL CANCER INSTITUTE1 May 2023 - 30 Apr 2026
    NIH NATIONAL CANCER INSTITUTE
  • EXTERNAL GRANT OR CONTRACT
    PHASE II PART I - ANALYSIS OF PRO-FULVESTRANT LEAD METABOLITES ON ER ACTIVITY IN ER WILDTYPE AND MUTANT BREAST CANCER CELL LINES
    1 Jan 2023 - 30 Jul 2023
  • EXTERNAL GRANT OR CONTRACT
    IN VIVO MULTIPLEXED SILENCING OF CIS-ELEMENTS IN THE BRAIN
    1 May 2021 - 30 Apr 2024
  • EXTERNAL GRANT OR CONTRACT
    GERTZ_SERMONIX PHARMACEUTICAL
    SERMONIX PHARMACEUTICALS INC4 Jan 2021 - 31 Dec 2021
    SERMONIX PHARMACEUTICALS INC
  • EXTERNAL GRANT OR CONTRACT
    THE ROLE OF REGULATORY PROTEINS IN ESTROGEN RECEPTOR ALPHA MUTANT BREAST CANCER
    1 Aug 2019 - 31 Jul 2023
  • EXTERNAL GRANT OR CONTRACT
    GERTZ_ZENO_SERD
    ZENO MANAGEMENT INC.9 May 2019 - 9 May 2020
    ZENO MANAGEMENT INC.
  • EXTERNAL GRANT OR CONTRACT
    MOLECULAR MODELING OF ESTROGEN
    ARMY MEDICAL RESEARCH ACQUISIT1 Jan 2016 - 31 Dec 2020
    ARMY MEDICAL RESEARCH ACQUISIT
  • EXTERNAL GRANT OR CONTRACT
    RNA-BASED BIOMARKERS
    NIH NATIONAL CANCER INSTITUTE9 Jan 2015 - 31 Dec 2019
    NIH NATIONAL CANCER INSTITUTE